leadf
logo-loader
viewQ BioMed Inc.

Q BioMed reveals technology partner Mannin Research is a member of the Canadian national COVID Cloud consortium

Mannin Research is developing a host-directed approach to treating patients with coronavirus (COVID-19) suffering from Acute Respiratory Distress Syndrome (ARDS)

Coronavirus
ARDS is a major severe complication of viral respiratory infections and the primary cause of mortality of COVID-19 patients

Q BioMed, Inc. (OTCQB:QBIO) has announced that its technology partner Mannin Research Inc., a private Canadian biotechnology company, is a member of the Canadian national COVID Cloud consortium. 

Mannin Research is developing a host-directed approach to treating patients with COVID-19 suffering from Acute Respiratory Distress Syndrome (ARDS). It is contributing to the development of the COVID-19 platform so as to provide information that will improve the effectiveness of its novel therapeutic for COVID-19 patients, code-named MAN-19.  

The platform will be used by Mannin Research to help understand, predict, and treat coronavirus (COVID-19) with molecular precision.

READ: Q BioMed receives recognition for its Strontium89 bone cancer pain relief advertisement

Q BioMed noted that the Canadian national consortium will expand development of a software platform for genomics and health data and apply it to COVID-19 research and drug development utilizing C$5.1 million in co-funding by Canada's Digital Technology Supercluster and aims to increase Canada's capacity to harness exponentially growing volumes of genomics and biomedical data to advance precision health.  

With a global death count of over 1.4 million people and record numbers of cases nationally, solutions that can help Canada respond to ongoing challenges of the pandemic are urgently needed.

The consortium is a collaboration between BioSymetrics, Centre of Genomics and Policy at McGill University, DNAstack, FACIT, Genome BC, Mannin Research, McMaster University, Microsoft Canada, Ontario Genomics, Ontario Institute for Cancer Research, Roche Canada, Sunnybrook Research Institute, and Vector Institute. It leverages past work of partners to address needs of infectious disease research with guidance from domain experts.

"We are very proud to contribute to such an important effort in Canada, as it will have an impact not only on Canadian's healthcare but on COVID-19 patients around the world, as we learn more about the disease and ways we can treat patients with it," said George N. Nikopoulos, President and CEO of Mannin Research in a statement.

Mannin Research is a research-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases. The company's main platform is built on the expertise in activation of Angiopoietin-Tie2 signalling pathway, a major regulator of vascular endothelium with a broad range of therapeutic applications.

Acute respiratory distress syndrome (ARDS) is a major severe complication of viral respiratory infections and the primary cause of mortality of COVID-19 patients. It is associated with profound vascular inflammation leading to pulmonary edema and hypoxemic respiratory failure.

In the face of the global COVID-19 pandemic, Mannin Research is developing novel therapeutics to stabilize lung endothelial barrier integrity and reduce vascular leakage. These therapeutics offer novel virus-independent, host-directed strategies to support patients with critical respiratory illness and prevent negative outcomes.

Q BioMed Inc. is a biotech acceleration and commercial-stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The company is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Contact the author at jon.hopkins@proactiveinvestors.com

Quick facts: Q BioMed Inc.

Price: 1.09 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $25.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed makes Strontium89 available to US urology doctors with purchasing...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has been awarded a contract with UroGPO, the largest group purchasing organization for urology private practice clinics in the US, to make its bone pain treatment Strontium89 available to doctors. Corin says through the partnership,...

3 weeks, 1 day ago

3 min read